# Phase 2 Study in Japanese Patients With Intermediate-2 or High Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis With Splenomegaly

> **NCT01692366** · PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 8 (actual)

## Conditions studied

- Myelofibrosis

## Interventions

- **DRUG:** SAR302503

## Key facts

- **NCT ID:** NCT01692366
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-11
- **Primary completion:** 2014-03
- **Final completion:** 2014-03
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2025-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01692366

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01692366, "Phase 2 Study in Japanese Patients With Intermediate-2 or High Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis With Splenomegaly". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT01692366. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*